ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för elacestrant. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

30 träffar

Bibliografisk träff 2024-02-21

US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer.

Shah M, Lingam H, Gao X, Gittleman H, Fiero MH, Krol D, Biel N, Ricks TK, Fu W, Hamed S, Li F, Sun JJ, Fan J, Schuck R, Grimstein M, Tang L, Kalavar S, Abukhdeir A, Pathak A, Ghosh S, Bulatao I, Tilley A, Pierce WF, Mixter BD, Tang S, Pazdur R, Kluetz P, Amiri-Kordestani L.

J Clin Oncol · research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1200/jco.23.02112

Bibliografisk träff 2023-12-19

Cost-effectiveness analysis of elacestrant versus standard endocrine therapy for second-/third-line treatment of patients with HR+/HER2- advanced or metastatic breast cancer: a US payer perspective.

Zeng W, Cao X, Lin J, Zheng B, Li N, Liu M, Cai H.

Front Oncol · research-article; journal article · DOI 10.3389/fonc.2023.1272586

Bibliografisk träff 2023-12-01

Correction: Elacestrant: First Approval.

Hoy SM.

Drugs · published erratum; correction · DOI 10.1007/s40265-023-01978-2

Bibliografisk träff 2023-12-01

Addressing unmet need in the management of patients with ER+/HER2-, ESR1-mutated metastatic breast cancer: clinician's perspective.

Rugo HS.

Clin Adv Hematol Oncol · review; journal article

Bibliografisk träff 2023-10-27

Elacestrant for ER-Positive HER2-Negative Advanced Breast Cancer.

Hageman E, Lussier ME.

Ann Pharmacother · review; journal article · DOI 10.1177/10600280231206131

Bibliografisk träff 2023-08-18

Oestrogen treatment restores dentate gyrus development in premature newborns by IGF1 regulation.

Sharma DR, Cheng B, Sahu R, Zhang X, Mehdizadeh R, Singh D, Iacobas D, Ballabh P.

J Cell Mol Med · research-article; journal article; research support, n.i.h., extramural · DOI 10.1111/jcmm.17816

Bibliografisk träff 2023-08-14

SCR-6852, an oral and highly brain-penetrating estrogen receptor degrader (SERD), effectively shrinks tumors both in intracranial and subcutaneous ER + breast cancer models.

Zhou F, Yang G, Xue L, Liu Y, Guo Y, Zhu J, Yuan L, Gu P, Tang F, Shan J, Tang R.

Breast Cancer Res · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/s13058-023-01695-4

Bibliografisk träff 2023-07-01

Advancing precision oncology in breast cancer: the FDA approval of elacestrant and Guardant360 CDx: a correspondence.

Abbasi HQ, Maryyum A, Khan AM, Shahnoor S, Oduoye MO, Wechuli PN.

Int J Surg · research-article; journal article · DOI 10.1097/js9.0000000000000334

Bibliografisk träff 2023-06-26

Erratum: Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.

Författaruppgift saknas

J Clin Oncol · published erratum · DOI 10.1200/jco.23.01239

Bibliografisk träff 2023-06-15

Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells.

Dubash TD, Bardia A, Chirn B, Reeves BA, LiCausi JA, Burr R, Wittner BS, Rai S, Patel H, Bihani T, Arlt H, Bidard FC, Kaklamani VG, Aftimos P, Cortés J, Scartoni S, Fiascarelli A, Binaschi M, Habboubi N, Iafrate AJ, Toner M, Haber DA, Maheswaran S.

Breast Cancer Res Treat · research-article; journal article · DOI 10.1007/s10549-023-06998-w

Bibliografisk träff 2023-06-14

Pharmacology and pharmacokinetics of elacestrant.

Beumer JH, Foldi J.

Cancer Chemother Pharmacol · research-article; journal article; research support, n.i.h., extramural · DOI 10.1007/s00280-023-04550-7

Bibliografisk träff 2023-05-16

Elacestrant: a new FDA-approved SERD for the treatment of breast cancer.

Bhatia N, Thareja S.

Med Oncol · review; journal article · DOI 10.1007/s12032-023-02045-2

Bibliografisk träff 2023-05-04

First Approval of Elacestrant as a Selective Estrogen Receptor Degrader for the Treatment of Metastatic Breast Cancer.

De SK.

Curr Med Chem · journal article · DOI 10.2174/0929867330666230504152352

Bibliografisk träff 2023-05-01

Elacestrant Dihydrochloride.

Författaruppgift saknas

Am J Health Syst Pharm · journal article · DOI 10.1093/ajhp/zxad050

Bibliografisk träff 2023-04-01

Elacestrant: First Approval.

Hoy SM.

Drugs · review-article; review; journal article · DOI 10.1007/s40265-023-01861-0

Bibliografisk träff 2023-03-23

Evaluating Elacestrant in the Management of ER-Positive, HER2-Negative Advanced Breast Cancer: Evidence to Date.

Varella L, Cristofanilli M.

Onco Targets Ther · review-article; review; journal article · DOI 10.2147/ott.s400563

Bibliografisk träff 2023-03-01

Elacestrant (Orserdu) for advanced or metastatic breast cancer.

Författaruppgift saknas

Med Lett Drugs Ther · journal article · DOI 10.58347/tml.2023.1671d

Bibliografisk träff 2023-02-20

Elacestrant: who are optimal candidates for the first oral SERD?

Lipsyc-Sharf M, Tolaney SM.

Ann Oncol · editorial · DOI 10.1016/j.annonc.2023.02.006

Bibliografisk träff 2022-11-29

Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer.

Pancholi S, Simigdala N, Ribas R, Schuster E, Leal MF, Nikitorowicz-Buniak J, Rega C, Bihani T, Patel H, Johnston SR, Dowsett M, Martin LA.

NPJ Breast Cancer · research-article; journal article · DOI 10.1038/s41523-022-00483-1

Bibliografisk träff 2022-07-01

Elacestrant Prolongs Progression-Free Survival in Advanced Breast Cancer.

Författaruppgift saknas

Cancer Discov · journal article · DOI 10.1158/2159-8290.cd-rw2022-095

Bibliografisk träff 2022-06-23

Elacestrant and the Promise of Oral SERDs.

Sanchez KG, Nangia JR, Schiff R, Rimawi MF.

J Clin Oncol · comment; research support, non-u.s. gov't; editorial · DOI 10.1200/jco.22.00841

Bibliografisk träff 2022-05-18

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.

Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, Mouret-Reynier MA, Sohn JH, Taylor D, Harnden KK, Khong H, Kocsis J, Dalenc F, Dillon PM, Babu S, Waters S, Deleu I, García Sáenz JA, Bria E, Cazzaniga M, Lu J, Aftimos P, Cortés J, Liu S, Tonini G, Laurent D, Habboubi N, Conlan MG, Bardia A.

J Clin Oncol · clinical trial, phase iii; research-article; randomized controlled trial; journal article · DOI 10.1200/jco.22.00338

Bibliografisk träff 2022-03-01

Elacestrant Improves Progression-Free Survival After Endocrine Therapy for Estrogen Receptor-Positive Metastatic Breast Cancer.

Jacobson A.

Oncologist · research-article; journal article · DOI 10.1093/oncolo/oyac015

Bibliografisk träff 2021-11-16

Elacestrant in metastatic breast cancer: Is the "standard of care" meeting standard requirements?

Olivier T, Prasad V.

Transl Oncol · brief-report; journal article · DOI 10.1016/j.tranon.2021.101273

Bibliografisk träff 2021-02-15

Early Signs of Response to Elacestrant Seen in ER+ HER2- Breast Cancer.

Författaruppgift saknas

Cancer Discov · journal article · DOI 10.1158/2159-8290.cd-rw2021-021

Bibliografisk träff 2021-01-29

Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer.

Bardia A, Kaklamani V, Wilks S, Weise A, Richards D, Harb W, Osborne C, Wesolowski R, Karuturi M, Conkling P, Bagley RG, Wang Y, Conlan MG, Kabos P.

J Clin Oncol · research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.1200/jco.20.02272

Bibliografisk träff 2020-09-11

A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using 18F-FES PET/CT imaging.

Jager A, de Vries EGE, der Houven van Oordt CWM, Neven P, Venema CM, Glaudemans AWJM, Wang Y, Bagley RG, Conlan MG, Aftimos P.

Breast Cancer Res · research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.1186/s13058-020-01333-3

Bibliografisk träff 2019-12-18

Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.

Patel HK, Tao N, Lee KM, Huerta M, Arlt H, Mullarkey T, Troy S, Arteaga CL, Bihani T.

Breast Cancer Res · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/s13058-019-1230-0

Bibliografisk träff 2019-08-20

EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer.

Bardia A, Aftimos P, Bihani T, Anderson-Villaluz AT, Jung J, Conlan MG, Kaklamani VG.

Future Oncol · clinical trial protocol; journal article · DOI 10.2217/fon-2019-0370

Bibliografisk träff 2017-05-04

Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models.

Bihani T, Patel HK, Arlt H, Tao N, Jiang H, Brown JL, Purandare DM, Hattersley G, Garner F.

Clin Cancer Res · journal article · DOI 10.1158/1078-0432.ccr-16-2561

Gå till forskningen.

Publikationer i urvalet

US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, <i>ESR1</i>-Mutated Advanced or Metastatic Breast Cancer.

Cost-effectiveness analysis of elacestrant versus standard endocrine therapy for second-/third-line treatment of patients with HR+/HER2- advanced or metastatic breast cancer: a US payer perspective.

Correction: Elacestrant: First Approval.

Addressing unmet need in the management of patients with ER+/HER2-, ESR1-mutated metastatic breast cancer: clinician's perspective.

Elacestrant for ER-Positive HER2-Negative Advanced Breast Cancer.

Oestrogen treatment restores dentate gyrus development in premature newborns by IGF1 regulation.

SCR-6852, an oral and highly brain-penetrating estrogen receptor degrader (SERD), effectively shrinks tumors both in intracranial and subcutaneous ER + breast cancer models.

Advancing precision oncology in breast cancer: the FDA approval of elacestrant and Guardant360 CDx: a correspondence.

Erratum: Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.

Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells.

Pharmacology and pharmacokinetics of elacestrant.

Elacestrant: a new FDA-approved SERD for the treatment of breast cancer.

First Approval of Elacestrant as a Selective Estrogen Receptor Degrader for the Treatment of Metastatic Breast Cancer.

Elacestrant Dihydrochloride.

Elacestrant: First Approval.

Evaluating Elacestrant in the Management of ER-Positive, HER2-Negative Advanced Breast Cancer: Evidence to Date.

Elacestrant (Orserdu) for advanced or metastatic breast cancer.

Elacestrant: who are optimal candidates for the first oral SERD?

Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer.

Elacestrant Prolongs Progression-Free Survival in Advanced Breast Cancer.

Elacestrant and the Promise of Oral SERDs.

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.

Elacestrant Improves Progression-Free Survival After Endocrine Therapy for Estrogen Receptor-Positive Metastatic Breast Cancer.

Elacestrant in metastatic breast cancer: Is the "standard of care" meeting standard requirements?

Early Signs of Response to Elacestrant Seen in ER<sup>+</sup> HER2<sup>-</sup> Breast Cancer.

Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer.

A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using <sup>18</sup>F-FES PET/CT imaging.

Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.

EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer.

Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER<sup>+</sup> Breast Cancer Patient-derived Xenograft Models.